Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01965327 · ClinicalTrials.gov registry record · Phase 2
Interferon Gamma-1b in Friedreich Ataxia (FRDA)
A Phase 2 study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01965327 is a Phase 2 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 12 participants.
The verdict
NCT01965327, a Phase 2 study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Friedreich ataxia (FRDA) is a progressive neurodegenerative disease of children and adults for which there is presently no therapy. Recently, a study reported that interferon gamma (IFN-g) could raise frataxin protein levels in both cell lines derived from patients with Friedreich ataxia and in a mouse model with Friedreich ataxia. The present study will test whether IFN-g is safe, tolerated and potentially efficacious in a heterogeneous cohort of children with FRDA.
Interventions
- DRUG Interferon Gamma-1b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01965327
The ClinicalTrials.gov registry entry for NCT01965327 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon Gamma-1b is the first listed.
NCT01965327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01965327 about?
NCT01965327 is a clinical study titled "Interferon Gamma-1b in Friedreich Ataxia (FRDA)". Friedreich ataxia (FRDA) is a progressive neurodegenerative disease of children and adults for which there is presently no therapy. Recently, a study reported that interferon gamma (IFN-g) could raise frataxin protein levels in both cell lines derived from patients with Friedreich ataxia and in a mo...
What is the current status of trial NCT01965327?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2013-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01965327?
The interventions under investigation include: Interferon Gamma-1b (DRUG).
Who is sponsoring clinical trial NCT01965327?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.